Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Energous Shares Charge 200% Higher After Receiving FCC Certification for Wireless Charging ...

Energous Shares Charge 200% Higher After Receiving FCC Certification for Wireless Charging Technology Shares of Energous Corp. skyrocketed after the company reported that it received certification from the FCC for its new, "groundbreaking" over-the-air, power-at-...

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia

Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/...

Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability'

Atara Biotherapeutics' clinical trial design and results are reviewed in a ROTH Capital Partners report. In a May 26 research note, ROTH Capital Partners analyst Tony Butler purported that Atara Biotherapeutics Inc.'s (ATRA:NASDAQ) "updated data from the Phase 1 ...

Could There Finally Be an Effective Treatment for Alzheimer's Disease?

ProMIS' preclinical treatment could possibly outshine Biogen's candidate. Finding an effective treatment for Alzheimer's disease has been elusive as many seemingly promising avenues of research did not prove out in clinical trials. Biogen Inc. (BIIB:NASDAQ) appeared...

Gapping Rotation in SPY and News Based Rallies Are A Warning

As holiday trading sets up in the global markets, the SPY is starting to show signs of volatility and warning of a potential top by gapping as price attempts to trade sideways. This type of top formation, along with the fact that the overnight REPO facility continues to roil t...

Steady Gold Amid Choppy Recovery

Initial jobless claims are declining painfully slowly. The disconnect between the choppy recovery and financial markets creates upward risk for gold. The initial jobless claims still paint grim picture . They amounted to 1.48 million in the week from June 13 to June 2...

Buzz on the Bullboards: Market rebound in 2024?

The end of the year is fast approaching but that doesn’t mean the markets have slowed down as the holidays quickly approach. Over the past five-day period, the S&P/TSX Composite has increased by 23 points to 20,862.86, while the S&P/TSX Venture Composi...

Buzz on the Bullboards: COVID-19 Testing Plays

There are many investing plays that are attractive to serious investors and small-cap opportunists in the current market, but coronavirus movements take the cake. We’ve noted that each sector has its share of positive opportunities for both long-term and sh...

Buzz on the Bullboards: Rising Tides…

Do rising tides truly lift all ships? The adage often holds true in investment circles, as strong markets or deals lift companies and competitors alike while negative sentiment can bring everyone in a sector down. But a rising tide is simply upwards pressure on companies, ...

NervGen: Are amazing human trial results leaking out?

“We are very excited! We are very, very excited!” So says Dr. Monica Perez, who is running the first human trial for a potential new wonder drug being developed by a tiny but well-financed life sciences start-up, NervGen Pharma Corp. ...
1 2 3 4 5 6 7 8 9 10